TrialLeukemia & lymphoma2015

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Koji Sasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.